- Home
- PSTV vs GOVX Comparison
PSTV vs GOVX Comparison
Compare PSTV & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTV
- GOVX
- Stock Information
- Founded
- PSTV 1996
- GOVX 2001
- Country
- PSTV United States
- GOVX United States
- Employees
- PSTV N/A
- GOVX N/A
- Industry
- PSTV Medical/Dental Instruments
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- PSTV Health Care
- GOVX Health Care
- Exchange
- PSTV Nasdaq
- GOVX Nasdaq
- Market Cap
- PSTV 17.0M
- GOVX 16.8M
- IPO Year
- PSTV N/A
- GOVX N/A
- Fundamental
- Price
- PSTV $0.89
- GOVX $0.57
- Analyst Decision
- PSTV Strong Buy
- GOVX Strong Buy
- Analyst Count
- PSTV 4
- GOVX 3
- Target Price
- PSTV $8.00
- GOVX $10.67
- AVG Volume (30 Days)
- PSTV 42.6M
- GOVX 1.0M
- Earning Date
- PSTV 11-13-2025
- GOVX 11-11-2025
- Dividend Yield
- PSTV N/A
- GOVX N/A
- EPS Growth
- PSTV N/A
- GOVX N/A
- EPS
- PSTV N/A
- GOVX N/A
- Revenue
- PSTV $5,317,000.00
- GOVX $6,143,044.00
- Revenue This Year
- PSTV $28.09
- GOVX N/A
- Revenue Next Year
- PSTV N/A
- GOVX N/A
- P/E Ratio
- PSTV N/A
- GOVX N/A
- Revenue Growth
- PSTV N/A
- GOVX 1943.07
- 52 Week Low
- PSTV $0.16
- GOVX $0.43
- 52 Week High
- PSTV $2.31
- GOVX $3.88
- Technical
- Relative Strength Index (RSI)
- PSTV 71.94
- GOVX 39.26
- Support Level
- PSTV $0.59
- GOVX $0.46
- Resistance Level
- PSTV $0.87
- GOVX $0.67
- Average True Range (ATR)
- PSTV 0.08
- GOVX 0.05
- MACD
- PSTV 0.04
- GOVX -0.01
- Stochastic Oscillator
- PSTV 91.32
- GOVX 46.60
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.